Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead program, ST101, for the treatment of advanced melanoma for patients in stages IIB through IV. This is the third orphan drug designation received for the ST101 program, following orphan designations by the FDA for the treatment of AML in April 2018 and for glioma in June 2020.
ST101 is a first-in-class peptide antagonist of C/EBPβ currently being evaluated in the Phase 2 portion of an ongoing Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumors that are refractory to standard therapy (NCT04478279). This study includes expansion cohorts that are currently dosing and enrolling patients with GBM, cutaneous melanoma, locally advanced or metastatic hormone-receptor positive breast cancer and castration-resistant prostate cancer.
Dr. Barry Kappel, Sapience’s CEO and President, commented, “Patients with advanced stage melanoma have very poor prognosis with a median survival of less than two years from diagnosis. The available treatments are limited, and many patients are refractory to targeted approaches or immunotherapy agents. With its unique mechanism of action targeting a key transcription factor C/EBPβ, we have a significant opportunity to deliver a novel therapeutic option with ST101. Our clinical plans remain on track, and we look forward to completing enrollment in all four expansion cohorts in Phase 2.”
Dr. Gina Capiaux, Sapience’s Vice President, Regulatory Affairs added, “Receiving our third Orphan Drug Designation is another important regulatory achievement that reinforces the FDA’s recognition of the potential of ST101 to improve clinical outcomes in patients with advanced melanoma. We look forward to quickly advancing the development of ST101 for patients in need.”
Orphan Drug Designation is granted to drugs or biological products for the treatment of rare diseases or conditions that impact fewer than 200,000 people in the United States. Incentives that come with the designation include eligibility for federal grants, research and development tax credits, waiver of filing fees, and the potential for a 7-year marketing exclusivity period. The designation does not alter the standard regulatory requirements and process for obtaining marketing approval. ST101 also previously received Fast Track Designation for recurrent GBM and advanced cutaneous melanoma in patients who have disease progression on or after anti-PD-1/anti-PD-L1 therapy.